Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
News
Featured News
Keya Medical’s FFR CT analysis DEEPVESSEL® is now available in the USA.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Keya Medical Scientists Advance Image Segmentation Methods
Keya Medical’s computer scientists, working with colleagues at the Shenzhen Second People’s Hospital, have devised a new method that significantly boosts segmentation accuracy and performance.
Keya Medical received the Best Clinical Aided Decision-Making Product Award at GAIR2021.
GAIR2021 released the annual Best AI Digital Intelligence List. In the medical field, Keya Medical received the Best Clinical Aided Decision-Making Product Award for its flagship product DeepVessel FFR.
Calcium Scoring from Coronary CT Angiography Using Deep Learning
Coronary Artery Calcium (CAC) scores have become increasingly important in assessing risk for coronary artery disease. Although non-contrast CT scans are typically used for CAC scoring, calculating CAC scores from CTAs directly could add further value to CTAs as a...
2021 ACC AHA Guideline Promotes Shared Decision-Making
The 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain was released on 28 October 2021. This report represents years of work by the Joint Committee on Clinical Practice Guidelines to define protocols and algorithms based on the evidence.
Beijing Anzhen Hospital Successfully Implements DeepVessel FFR
On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital.
What’s the future of health data interoperability using FHIR?
The future of health data interoperability using FHIR. ONC’s Micky Tripathi provided his perspective at a recent Cambia Grove forum.
Can AI Help Improve Atherosclerotic Plaque Quantification?
Artificial intelligence and other advanced informatics could be applied to coronary CTA images to unlock valuable information on atherosclerotic plaque characteristics that could be used to personalize care decisions. Learn more.
Medical Imaging AI Fee-for-Service and the Transition to Value-Based Care
Learn more about the encouraging recent developments in the use of targeted fee-for-service models as a transition strategy to ensure that patients have access to proven advanced diagnostics and treatments.
Coronary CTA Reimbursement: Opportunities & Challenges
Examine the current challenges for coronary CTA reimbursement, the potential effects it will have on patient care, and what medical imagers can do to help improve reimbursement moving forward.
Keya Medical Showcases DeepVessel FFR at World Artificial Intelligence Conference 2021
Keya Medical showcased its deep learning-based diagnostic and treatment solutions at the World Artificial Intelligence Conference 2021 (WAIC 2021) held in Shanghai.
Products
DeepVessel FFR
CuraRad-ICH
Solutions
All Solutions
Diagnostic Solutions
Treatment Solutions
Solution Suites
